Related Experiment Video

Updated: Jul 10, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Engineering immune therapy against hepatitis B virus

Fazle Akbar1, Osamu Yoshida, Masanori Abe

  • 1Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan.

Hepatology Research : the Official Journal of the Japan Society of Hepatology
|October 13, 2007
PubMed

Insights

Chronic hepatitis B virus (HBV) infection affects millions globally, with current treatments offering limited efficacy. This research explores novel HBV-specific immune therapies to improve treatment outcomes for chronic HBV carriers.

Area of Science:

  • Immunology
  • Hepatology
  • Virology

Background:

  • Chronic hepatitis B virus (HBV) infection impacts 350-400 million people worldwide, leading to severe liver diseases.
  • Current antiviral treatments for chronic HBV are insufficient, failing to eradicate the virus and often causing side effects.
  • Host immune responses are critical in HBV infection, influencing disease progression and treatment response.

Purpose of the Study:

  • To review the role of immune responses in chronic HBV infection.
  • To evaluate the limitations of current antiviral therapies and vaccine therapy for chronic HBV.
  • To propose a framework for developing more effective HBV-specific immune therapies.

Main Methods:

  • Literature review on HBV immunology and current treatment strategies.
  • Analysis of the efficacy and limitations of existing antiviral agents and vaccine therapy.
  • Conceptualization of novel HBV-specific immune therapy approaches.

Main Results:

  • Existing antiviral drugs offer only partial efficacy and cannot eliminate HBV.
  • Current vaccine therapy approaches for chronic HBV carriers show limited long-term success.
  • HBV-specific immunity is crucial for controlling viral load and disease progression.

Conclusions:

  • There is a need for improved therapeutic strategies beyond current antiviral and vaccine approaches.
  • Engineering potent HBV-specific immune therapies holds promise for treating chronic HBV infection.
  • Further research into vaccine/host interactions is essential for advancing HBV immunotherapy.

More Related Videos

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...